Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Lifted by DeepCurrents Investment Group LLC

DeepCurrents Investment Group LLC increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 28.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 66,603 shares of the specialty pharmaceutical company’s stock after buying an additional 14,550 shares during the period. DeepCurrents Investment Group LLC owned about 0.11% of Jazz Pharmaceuticals worth $7,068,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Philip James Wealth Mangement LLC grew its holdings in shares of Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after purchasing an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after purchasing an additional 24,850 shares during the period. Inspire Investing LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter worth $689,000. Baird Financial Group Inc. acquired a new stake in Jazz Pharmaceuticals in the first quarter worth $539,000. Finally, Kennedy Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $1,100,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In other news, Director Rick E. Winningham sold 5,500 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the transaction, the director directly owned 8,893 shares in the company, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the completion of the sale, the executive vice president owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This trade represents a 8.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 127,053 shares of company stock worth $22,366,046 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 1.7%

Shares of NASDAQ:JAZZ opened at $164.97 on Thursday. The company has a 50 day moving average of $149.81 and a 200-day moving average of $128.44. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. The firm has a market cap of $10.02 billion, a P/E ratio of -27.18, a P/E/G ratio of 3.65 and a beta of 0.30. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99.

Analyst Ratings Changes

Several equities analysts have recently commented on JAZZ shares. The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday. JPMorgan Chase & Co. dropped their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Piper Sandler reaffirmed an “overweight” rating and set a $219.00 price target (up previously from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday. Finally, Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $200.47.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.